Irritable Bowel Syndrome Treatment Market Analysis By Key Players, SWOT Analysis, Growth Factors, and Forecast till 2034

Home - News & Society - Irritable Bowel Syndrome Treatment Market Analysis By Key Players, SWOT Analysis, Growth Factors, and Forecast till 2034
fact.mr

It is projected that the North American market for treatments for irritable bowel syndrome (IBS) would produce around US$ 1,722 million in sales by 2024. The North American market is being driven by customized IBS treatment solutions since patient-centric care models are becoming more and more popular in the US and Canada.

ย The market for treatments for irritable bowel syndrome is predicted to grow at a compound annual growth rate (CAGR) of 8.7% between 2024 and 2034, based on Fact.MR’s study of market trends. By the end of 2034, the industry’s net valuation is predicted to reach a whopping US$ 9,355.4 million if this profitable growth rate continues.

๐ƒ๐จ๐ฐ๐ง๐ฅ๐จ๐š๐ ๐š ๐’๐š๐ฆ๐ฉ๐ฅ๐ž ๐‚๐จ๐ฉ๐ฒ ๐จ๐Ÿ ๐“๐ก๐ข๐ฌ ๐‘๐ž๐ฉ๐จ๐ซ๐ญ:ย https://www.factmr.com/connectus/sample?flag=S&rep_id=9520

The industry’s present and upcoming technical and financial facts are accessible in the Irritable Bowel Syndrome Treatment Market 2024 Report. It is among the most extensive and significant additions to the library of market research studies from Prudent Markets. It provides thorough investigation and evaluation of the major facets of the worldwide market for treatments for irritable bowel syndrome. This study examines every significant aspect influencing the expansion of the worldwide market for treatments for irritable bowel syndrome, including the demand-supply situation, pricing strategies, profit margins, production, and value chain analysis.

Regional Analysis for Irritable Bowel Syndrome Treatment Market:

  • North Americaย (the USA and Canada)
  • Europeย (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
  • Asia Pacificย (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
  • Latin America(Brazil, Mexico and Rest of Latin America)
  • Middle East & Africa(South Africa, GCC and Rest of the Middle East & Africa)

Competitive Landscape

The emergence of players concentrating on other healthcare services earlier has made the global network of suppliers of irritable bowel syndrome treatment services more competitive. Due to the rising need for IBS patients’ healthcare, small-scale market participants have gained prominence recently, especially in emerging economies.

Recent Developments by Irritable Bowel Syndrome Treatment Industry Participants

To raise awareness among patients with gastrointestinal diseases, Abbott Laboratories and the Nutrition Society of India collaborated to give clinical dietary recommendations specifically customized for the Indian market in March 2021. GI conditions such as functional constipation, peptic ulcers, chronic pancreatitis, and irritable bowel syndrome are anticipated to generate sufficient economic possibilities for Abbott in the nation.

Ferring B.V., a biopharmaceutical business, announced in June 2022 that it has teamed with I-MAB Biopharma Limited, a well-known biopharma company with an emphasis on innovation. Olamkicept is a selective interleukin-6 (IL-6) trans-signaling inhibitor that is being developed by the two businesses to treat inflammatory bowel disease (IBD) and related inflammatory diseases.

๐†๐ž๐ญ ๐‚๐ฎ๐ฌ๐ญ๐จ๐ฆ๐ข๐ณ๐š๐ญ๐ข๐จ๐ง ๐จ๐ง ๐ญ๐ก๐ข๐ฌ ๐‘๐ž๐ฉ๐จ๐ซ๐ญ ๐Ÿ๐จ๐ซ ๐’๐ฉ๐ž๐œ๐ข๐Ÿ๐ข๐œ ๐‘๐ž๐ฌ๐ž๐š๐ซ๐œ๐ก ๐’๐จ๐ฅ๐ฎ๐ญ๐ข๐จ๐ง๐ฌ:ย https://www.factmr.com/connectus/sample?flag=RC&rep_id=9520

Key Segments Covered by Irritable Bowel Syndrome Treatment Industry Survey Report

  • By Poduct Type:
    • Fiber Supplements
    • Anti-Diarrheal
    • Anticholinergic and Antispasmodic
    • Antidepressant
    • Antibiotics
    • Alosetron
    • Lubiprostone
    • Linaclotide
    • NHE3
  • By Indication:
    • Irritable Bowel Syndrome with Constipation
    • Irritable Bowel Syndrome with Diarrhea
    • Irritable Bowel Syndrome with Alternating Constipation and Diarrhea
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Drug Stores
    • Online Pharmacies and Stores
    • Hypermarkets and Supermarkets
    • Other Distribution Channels
  • By Region:
    • North America
    • Europe
    • Latin America
    • East Asia
    • South Asia & Oceania
    • The Middle East & Africa (MEA)

๐‚๐จ๐ง๐ญ๐š๐œ๐ญ:

US Sales Office11140 Rockville PikeSuite 400Rockville, MD 20852United StatesTel: +1 (628) 251-1583, +353-1-4434-232

Email: sales@factmr.com

Table of Contents

nainad